Johnson & Johnson’s DePuy Synthes has acquired Sentio, which makes nerve localization technology for spine surgery, for an undisclosed amount.
Nerve localization technologies help physicians avoid injuring nerves while performing spine procedures. Most systems use several needle electrodes in the patient’s limbs to locate motor neurons in the spine. They then generate signals that a neuromonitoring specialist interprets, guiding the surgeon.
However, neurologic complications persist in spite of these nerve localization systems, DePuy said in a statement. These complications, including pain or weakness in the hip or leg, result from the bruising or stretching of nerves near the surgical area. Temporary complications affect 9.4% of patients, while permanent complications are reported in 2.5% of patients, a study showed.
Enter Sentio, which uses adhesive sensors placed on the skin at relevant muscle groups and gives the surgeon feedback in real time. Sentio’s system does not require a specialist to set it up or to interpret signals.
“With Sentio’s nerve localization technology, DePuy Synthes will strengthen its spine portfolio in decompression procedures as well as lateral surgery, and build a platform for future innovation in minimally invasive surgery,” said Ciro Römer, DePuy Synthes chairman, in the statement. “The surgeon-driven approach will also help us reach more customers operating in an ambulatory surgery setting. This acquisition underscores our commitment to investing in differentiated technologies that help us reach more customers and patients around the world.”
Sentio initially focused on a narrow market in southeast Michigan, but DePuy plans to use its network to roll the system out globally.
By Amirah Al Idrus
Source: Fierce Biotech
The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.
BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.
Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.
